NCT00852397 - A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Acute Coronary Syndrome

Interventions

DRUG

Apixaban

Apixaban 2.5 mg tablet BID for 24 weeks

DRUG

Apixaban

Apixaban 5.0 mg tablet BID for 24 weeks

OTHER

Placebo

Placebo tablet for 24 weeks

Trial Locations (18)

Pfizer Investigational Site, Kasuga

Pfizer Investigational Site, Kitakyushu

Pfizer Investigational Site, Gifu

Pfizer Investigational Site, Hiroshima

Pfizer Investigational Site, Kure

Pfizer Investigational Site, Sapporo

Pfizer Investigational Site, Kumamoto

Pfizer Investigational Site, Uji

Pfizer Investigational Site, Ikoma

Pfizer Investigational Site, Hirakata

Pfizer Investigational Site, Kawachi-Nagano

Pfizer Investigational Site, Matsubara

Pfizer Investigational Site, Osaka

Pfizer Investigational Site, Yao

Pfizer Investigational Site, Wako

Pfizer Investigational Site, Sunto

Pfizer Investigational Site, Minato-Ku

Pfizer Investigational Site, Shinagawa